Literature DB >> 15355884

Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.

Eileen Brantley1, Valentina Trapani, Michael C Alley, Curtis D Hose, Tracey D Bradshaw, Malcolm F G Stevens, Edward A Sausville, Sherman F Stinson.   

Abstract

Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles possess potent antiproliferative activity against certain cancer cells, similar to the unfluorinated 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495). In "sensitive" cancer cells, DF 203 is metabolized by, can induce expression of, and binds covalently to CYP1A1. Metabolism appears to be essential for its antiproliferative activity through DNA adduct formation. However, a biphasic dose-response relationship compromises its straightforward development as a chemotherapeutic agent. We investigated whether fluorinated benzothiazoles inhibit cancer cell growth without the biphasic dose-response, and whether the fluorinated benzothiazoles are also metabolized into reactive species, with binding to macromolecules in sensitive cancer cells. One fluorinated benzothiazole, 2-(4-amino-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) did exhibit potent, antiproliferative activity without a biphasic dose-response. The fluorinated benzothiazoles were also metabolized only in cells, which subsequently showed evidence of cell death. We used microsomes from genetically engineered human B-lymphoblastoid cells expressing cytochromes P450 (CYP1A1, CYP1A2, or CYP1B1) to clarify the basis for fluorinated benzothiazole metabolism. 5F 203 induced CYP1A1 and CYP1B1 mRNA expression in sensitive breast and renal cancer cells, whereas 5F 203 induced CYP1A1 mRNA but not CYP1B1 mRNA expression in sensitive ovarian cancer cells. 5F 203 did not induce CYP1A1 or CYP1B1 mRNA expression in any "resistant" cancer cells. The fluorinated benzothiazoles induced CYP1A1 protein expression exclusively in sensitive cells. [14C]5F 203 bound substantially to subcellular fractions in sensitive cells but only minimally in resistant cells. These data are concordant with the antiproliferative activity of fluorinated benzothiazoles deriving from their ability to become metabolized and bind to macromolecules within sensitive cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15355884     DOI: 10.1124/dmd.104.001057

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  15 in total

1.  Comparative proteomics among cytochrome p450 family 1 for differential substrate specificity.

Authors:  Siddharth S Kesharwani; Prajwal P Nandekar; Preeti Pragyan; Abhay T Sangamwar
Journal:  Protein J       Date:  2014-12       Impact factor: 2.371

2.  Characterization of the 4-(benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model antitumor drug.

Authors:  Mrinal Chakraborty; Kyoung Joo Jin; Stephen A Glover; Michael Novak
Journal:  J Org Chem       Date:  2010-08-06       Impact factor: 4.354

3.  Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1.

Authors:  Kai Wang; F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2012-07-10       Impact factor: 3.739

4.  tert-Butyl N-[6-(N,N-dipropyl-carbamo-yl)-1,3-benzothia-zol-2-yl]carbamate.

Authors:  Xin Fang; Can Lei; Hai-Yang Yu; Ming-Dong Huang; Jun-Dong Wang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-04-30

5.  Aryl Hydrocarbon Receptor Ligand 5F 203 Induces Oxidative Stress That Triggers DNA Damage in Human Breast Cancer Cells.

Authors:  Lancelot S McLean; Cheri N Watkins; Petreena Campbell; Dain Zylstra; Leah Rowland; Louisa H Amis; Lia Scott; Crystal E Babb; W Joel Livingston; Agus Darwanto; Willie L Davis; Maheswari Senthil; Lawrence C Sowers; Eileen Brantley
Journal:  Chem Res Toxicol       Date:  2015-04-01       Impact factor: 3.739

Review 6.  The expanding role of prodrugs in contemporary drug design and development.

Authors:  Jarkko Rautio; Nicholas A Meanwell; Li Di; Michael J Hageman
Journal:  Nat Rev Drug Discov       Date:  2018-04-27       Impact factor: 84.694

7.  Exploring CYP1A1 as anticancer target: homology modeling and in silico inhibitor design.

Authors:  Abhay T Sangamwar; Leena B Labhsetwar; Sharad V Kuberkar
Journal:  J Mol Model       Date:  2008-07-30       Impact factor: 1.810

8.  Ethyl 2-(tert-butoxy-carbonyl-amino)-1,3-benzothia-zole-6-carboxyl-ate.

Authors:  Can Lei; Xin Fang; Hai-Yang Yu; Ming-Dong Huang; Jun-Dong Wang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-03-24

Review 9.  Cytochrome P450-activated prodrugs.

Authors:  Paul R Ortiz de Montellano
Journal:  Future Med Chem       Date:  2013-02       Impact factor: 3.808

Review 10.  Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention.

Authors:  Vasilis P Androutsopoulos; Aristidis M Tsatsakis; Demetrios A Spandidos
Journal:  BMC Cancer       Date:  2009-06-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.